Found: 3
Select item for more details and to access through your institution.
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 11, p. 1244, doi. 10.1002/ajh.25627
- By:
- Publication type:
- Article
Targeted Cancer Immunotherapy by Nanoparticle T Cell Engagers.
- Published in:
- FASEB Journal, 2022, v. 36, p. N.PAG, doi. 10.1096/fasebj.2022.36.S1.R2489
- By:
- Publication type:
- Article
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 1, p. 36, doi. 10.1111/bjh.14807
- By:
- Publication type:
- Article